Global Pharmaceutical Solid Dosage Contract Manufacturing Market Growth (Status and Outlook) 2023-2029

Global Pharmaceutical Solid Dosage Contract Manufacturing Market Growth (Status and Outlook) 2023-2029

The pharmaceuticals solid dosage contract manufacturing comes under the category of the pharmaceutical formulations. It is the largest segment of all the type of the pharmaceutical formulation outsourcing.

LPI (LP Information)' newest research report, the “Pharmaceutical Solid Dosage Contract Manufacturing Industry Forecast” looks at past sales and reviews total world Pharmaceutical Solid Dosage Contract Manufacturing sales in 2022, providing a comprehensive analysis by region and market sector of projected Pharmaceutical Solid Dosage Contract Manufacturing sales for 2023 through 2029. With Pharmaceutical Solid Dosage Contract Manufacturing sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Pharmaceutical Solid Dosage Contract Manufacturing industry.

This Insight Report provides a comprehensive analysis of the global Pharmaceutical Solid Dosage Contract Manufacturing landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Pharmaceutical Solid Dosage Contract Manufacturing portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Pharmaceutical Solid Dosage Contract Manufacturing market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Pharmaceutical Solid Dosage Contract Manufacturing and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Pharmaceutical Solid Dosage Contract Manufacturing.

The global Pharmaceutical Solid Dosage Contract Manufacturing market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Pharmaceutical Solid Dosage Contract Manufacturing is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Pharmaceutical Solid Dosage Contract Manufacturing is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Pharmaceutical Solid Dosage Contract Manufacturing is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Pharmaceutical Solid Dosage Contract Manufacturing players cover Abbott Laboratories, Catalent Pharma Solutions, Jubilant Life Sciences Limited, Alkermes, BioPharma Solutions, Cytovance Biologics, DPT Laboratories, Fresenius Kabi and Halo Pharmaceutical, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Pharmaceutical Solid Dosage Contract Manufacturing market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Tablets
Capsule
Lozenge
Powder
Others

Segmentation by application
Instant Release
Sustained Release
Extended Release
Effervescent Tablets
Chewable Tablets
Enteric Release

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Abbott Laboratories
Catalent Pharma Solutions
Jubilant Life Sciences Limited
Alkermes
BioPharma Solutions
Cytovance Biologics
DPT Laboratories
Fresenius Kabi
Halo Pharmaceutical
Lyophilization Technology
Mikart
Pillar5 Pharma
Haupt Pharma
Althea Technologies
Associates of Cape Cod
Covance
Emergent BioSolutions

Please note: The report will take approximately 2 business days to prepare and deliver.